I appreciate the response here and want to clarify my argument a bit. I totally understand that currently available SUT isn’t sufficient to make cultured meat cost-effective. I’m mostly arguing against the notion that these problems are intractable. To your point about the difficulties with gamma irradiation, it seems likely that there could be a reasonable alternative to gamma irradiation for SUT sterilization. At the moment, pharma companies get by just fine using stainless steel for processes > 2kL, so there isn’t much pressure to improve from that angle. If single-use is truly enabling for cultured meat, then that provides an impetus for more investment in improved sterilization technologies.
The purported economic and environmental benefits of SUT are related to the elimination of sterilization steam (because everything is gamma-sterilized before shipping) and the elimination of cleaning chemicals (because the bags are not cleaned for reuse).
The major cost savings I see for a cultured meat plant would be in a reduction in the requirements for air quality. A fully single use plant with completely aseptic connections can (in-theory) be run aseptically without a clean room. There would just be a small clean room for media and solution prep. Existing pharma plants using SUT tend to still need high quality air as there are some steps in the process that require manual manipulation. I’ve seen it suggested though that future biopharma processes which use fully integrated and continuous systems can be run in clean rooms with drastically lower air quality than existing plants.
Combined with 100% manual unpacking, setting, connect/disconnect, and teardown of bags, the single-use idea seemed very much at odds with the fully automatic plant that many propose.
Moving to long duration perfusion (> 30 days) reduces the need for unpacking / teardown. There have been biopharma companies which have demonstrated the ability to run stable perfusion for up to 60 days. For the most part, companies haven’t gone longer than that mostly because it’s not really necessary.
I appreciate the response here and want to clarify my argument a bit. I totally understand that currently available SUT isn’t sufficient to make cultured meat cost-effective. I’m mostly arguing against the notion that these problems are intractable. To your point about the difficulties with gamma irradiation, it seems likely that there could be a reasonable alternative to gamma irradiation for SUT sterilization. At the moment, pharma companies get by just fine using stainless steel for processes > 2kL, so there isn’t much pressure to improve from that angle. If single-use is truly enabling for cultured meat, then that provides an impetus for more investment in improved sterilization technologies.
The major cost savings I see for a cultured meat plant would be in a reduction in the requirements for air quality. A fully single use plant with completely aseptic connections can (in-theory) be run aseptically without a clean room. There would just be a small clean room for media and solution prep. Existing pharma plants using SUT tend to still need high quality air as there are some steps in the process that require manual manipulation. I’ve seen it suggested though that future biopharma processes which use fully integrated and continuous systems can be run in clean rooms with drastically lower air quality than existing plants.
Moving to long duration perfusion (> 30 days) reduces the need for unpacking / teardown. There have been biopharma companies which have demonstrated the ability to run stable perfusion for up to 60 days. For the most part, companies haven’t gone longer than that mostly because it’s not really necessary.